Canadian patients suffering from restless legs syndrome (RLS) now have access to Relaxis—the only medical device approved by the US Food and Drug Administration for treating the symptoms of primary RLS. This is thanks to an exclusive new agreement between Sleep Therapeutics and Sensory NeuroStimulation Inc, maker of the Relaxis technology.
Headquartered in Edmonton, with clinics located throughout Canada, Sleep Therapeutics has been helping Canadians sleep better since 2001. Relaxis is Health Canada Licensed and CSA certified.
“Providing RLS sufferers with a non-pharmaceutical solution to improve their sleep quality will enable our exceptional staff and company to help more people awaken their best lives,” says Lionel Marshall, CEO of Sleep Therapeutics, in a release. Marshall, who has over 20 years of industry experience, knows firsthand the effects of poor quality sleep. After optimizing treatment for his own sleep disorder, he experienced such a vast improvement in his life that he was motivated to start the company and help others experience better quality sleep.